secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2021-07-09T23:59:59+00:00
Accession:  0001104659-21-090634
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics names C. Russell Trenary III CEO; Lawrence Kenyon stays CFO
--------------------------------------------------------------------------------

- C. Russell Trenary III appointed President & CEO effective July 6, 2021; replaces Lawrence Kenyon who remains CFO.
- Base salary $600,000; target annual cash bonus of 70% of base salary.
- Received initial grant of 4,000,000 options + performance grant of 1,000,000 options with milestone vesting.
- Company on track for NORSE TWO top-line data Q3 2021; plans BLA submission for ONS-5010 in Q1 2022.
- Trenary previously led InnFocus through acquisition by Santen; over 35 years in life sciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/0001104659-21-090634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/tm2121712d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-090634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer